Lipid reducing and antioxidant action of mexicor in patients with diabetes mellitus type 2
Klebanova, E.M.; Balabolkin, M.I.; Kreminskaia, V.M.; Smirnov, L.D.
Terapevticheskii Arkhiv 78(8): 67-70
2006
ISSN/ISBN: 0040-3660 PMID: 17078221 Document Number: 2607
Aim. To study mexicor effects on functional activity of beta-cells, insulin resistance, lipid metabolism and lipid peroxidation in patients with diabetes mellitus (DM) type 2.Material and methods. Twenty patients with DM type 2 participated in a double blind randomized trial of mexicor vs placebo. Before and after therapy the following parameters were studied: plasma glucose before meal, immunoreactive insulin, glycosilated hemoglobin, cholesterol, triglycerides, LDLP and HDLP cholesterol, malonic dialdehyde, dienic conjugates, superoxide dismutase, catalase, glutathione peroxidase and alpha-tocopherol.Results. Mexicor significantly improved compensation of carbohydrate metabolism. by glucose and glycosylated hemoglobin in the blood, insulin resistance value, lipid metabolism and lipid peroxidation in activation of antioxidant enzymes.Conclusion. Mexicor in therapy of DM type 2 improves carbohydrate and lipid metabolism, lipid peroxidation, activates antioxidant defence enzymes, functional activity of beta-cells, reduces insulin resistance.
Document emailed within 1 workday
